Myelodysplastic Syndrome Market Set for Significant Shift by 2034 Driven by Innovative Pipeline and Growing Patient Burden, Reports DelveInsight

The Myelodysplastic Syndrome (MDS) Market exceeded USD 2.8 billion in 2023 across the 7MM, with the US contributing the largest share. By 2034, Germany is projected to lead revenue among the EU4 and the UK, followed by France. The US reported around 21,000 incident cases in 2023, a number expected to grow through 2034. Low-risk MDS represented the highest incident cases, while SF3B1 and TET2 mutations were the most common, accounting for approximately 25% and 20% of US cases, respectively.

Key regulatory and pipeline updates include the EU approval expansion of REBLOZYL (luspatercept) in April 2024 for first-line treatment in lower-risk MDS. Meanwhile, Gilead's magrolimab program faced setbacks with a full FDA clinical hold in February 2024, and Novartis discontinued sabatolimab in January 2024 following negative Phase III outcomes and portfolio reprioritization.

DelveInsight's latest report, "Myelodysplastic Syndrome Market Insight, Epidemiology, and Market Forecast - 2034," offers a comprehensive analysis of the historical and projected epidemiology, market landscape, and treatment dynamics of Myelodysplastic Syndrome (MDS) across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Gain exclusive access to critical intelligence on market trends, therapeutic developments, and pipeline innovations. Download the full report here: Myelodysplastic Syndrome Market Size - https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Myelodysplastic Syndrome Market Report
• November 10, 2025: Bristol Myers Squibb initiated a study evaluating the safety and efficacy of Luspatercept at its maximum approved dose in low-risk MDS patients requiring RBC transfusions.
• November 5, 2025: Takeda launched a study assessing the safety, tolerability, and dose response of elritercept in adults with anemia linked to lower-risk MDS, with additional objectives to evaluate MDS progression and its effects on healthy RBC production.
• In 2023, the US reported the highest number of incident Myelodysplastic Syndrome cases within the 7MM, with approximately 21,000 cases, a figure projected to rise during the forecast period.
• Individuals aged 80+ accounted for nearly 40% of total incident cases in the US in 2023.
• RAEB/MDS-EB represented the most common subtype in the US.
• Within EU4 and the UK, Germany recorded the highest incidence, followed by France, while Spain had the lowest number of cases in 2023.
• Key Myelodysplastic Syndrome companies include Bristol-Myers Squibb, Astex Pharmaceuticals, Taiho Oncology, Fibrogen, AbbVie, Gilead Sciences, Novartis, Syros Pharmaceuticals, Takeda, Pfizer, Geron, Karyopharm Therapeutics, Antengene, BerGenBio, Jazz Pharmaceuticals, Aprea Therapeutics, Sanofi, Medac, and others.
• Prominent Myelodysplastic Syndrome therapies in use or development include Deferasirox, Tebapivat, KER-050, Luspatercept, Epoetin Alfa, among others.

Stay competitive in the evolving MDS landscape. Access the full strategic report here: Myelodysplastic Syndrome Treatment Market Size - https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelodysplastic Syndrome Epidemiology Segmentation - 7MM
Total incident Myelodysplastic Syndrome population
Age-specific incidence
Subtype-specific incidence
Risk-specific incidence
Mutation-specific incidence

Explore the drivers shaping MDS epidemiology: Myelodysplastic Syndrome Prevalence - https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelodysplastic Syndrome Marketed Therapies
VIDAZA (azacitidine) - Bristol Myers Squibb
A pyrimidine nucleoside analog that induces DNA hypomethylation and cytotoxicity in abnormal bone marrow cells. Approved by the FDA in May 2004, it remains a foundational MDS therapy.

DACOGEN (decitabine) - Johnson & Johnson
A nucleoside metabolic inhibitor targeting adult MDS patients across multiple categories. By promoting DNA hypomethylation and interrupting transcriptional dysregulation, DACOGEN helps restore normal cellular differentiation. FDA approval was granted in May 2006.

Myelodysplastic Syndrome Emerging Therapies
Venetoclax - AbbVie
A first-in-class BCL-2 inhibitor currently in Phase III trials for newly diagnosed higher-risk MDS. The combination therapy received Breakthrough Therapy Designation in July 2021.

Tamibarotene - Syros Pharmaceuticals
An oral, selective RARα agonist developed for genetically defined patient groups with RARA overexpression. It is being evaluated in the Phase III SELECT-MDS-1 trial for newly diagnosed higher-risk MDS patients.

Insights into the Myelodysplastic Syndrome Drug Pipeline
A substantial range of targeted agents-such as BCL-2 inhibitors, IDH1/2 inhibitors, and FLT3 inhibitors-are under development and show promise in modifying disease progression. Venetoclax remains one of the most potent candidates to date, while newer investigational options may improve precision-based treatment strategies for patients lacking effective therapies.

Myelodysplastic Syndrome Market Outlook
Historically, Myelodysplastic Syndrome treatment has relied on a limited set of regimens with modest outcomes, particularly for patients who fail HMAs. However, recent advancements introduce a wave of targeted therapies and investigational agents designed to improve patient response and broaden therapeutic options. As clinical innovation accelerates, the therapeutic landscape is expected to shift significantly over the forecast period.

Learn more about ongoing clinical trials, market dynamics, and future opportunities: Myelodysplastic Syndrome Ongoing Clinical Trials Analysis - https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Report
• Coverage- 7MM
• Study Period- 2020-2034
• Myelodysplastic Syndrome Companies- Bristol-Myers Squibb, Astex Pharmaceutical, Taiho Oncology, Fibrogen, AbbVie, Gilead Sciences, Novartis, Syros Pharmaceuticals, Takeda, Pfizer, Geron Corporation, Karyopharm Therapeutics, Antengene Corporation, BerGenBio ASA, Jazz Pharmaceuticals, Aprea Therapeutics, Sanofi, Medac and others.
• Myelodysplastic Syndrome Therapies- Deferasirox, Tebapivat, KER-050, Luspatercept, Epoetin Alfa, and others.
• Myelodysplastic Syndrome Therapeutic Assessment: Myelodysplastic Syndrome Current Marketed and Myelodysplastic Syndrome Emerging Therapies
• Myelodysplastic Syndrome Market Dynamics: Myelodysplastic Syndrome market drivers and Myelodysplastic Syndrome market barriers
• Myelodysplastic Syndrome Unmet Needs, KOL's views, Analyst's views, Myelodysplastic Syndrome Market Access and Reimbursement

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.